WO2009064029A1 - Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate - Google Patents
Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate Download PDFInfo
- Publication number
- WO2009064029A1 WO2009064029A1 PCT/JP2008/071167 JP2008071167W WO2009064029A1 WO 2009064029 A1 WO2009064029 A1 WO 2009064029A1 JP 2008071167 W JP2008071167 W JP 2008071167W WO 2009064029 A1 WO2009064029 A1 WO 2009064029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- reaction
- mmol
- Prior art date
Links
- 0 CC(CC(CCC1OC(CCC=O)CC1=C)OC1C[C@@](C2*C(C[C@@](CC[C@@]3OC([C@@](*)C=CI)[C@@](*)[C@@](*)C3)OC)=O)OC(CC(*)C*)[C@@]2OC)C1=C Chemical compound CC(CC(CCC1OC(CCC=O)CC1=C)OC1C[C@@](C2*C(C[C@@](CC[C@@]3OC([C@@](*)C=CI)[C@@](*)[C@@](*)C3)OC)=O)OC(CC(*)C*)[C@@]2OC)C1=C 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
Definitions
- the present invention relates to a novel compound represented by formula (I) shown below and a method for producing the same, and a method for producing a compound represented by formula (III) shown below from the compound (I), especially a novel desulfonylation reaction.
- Halichondrin B is a natural product having potent anti-tumor activity, which was isolated first from the marine sponge Halichondria okadai and subsequently discovered in Axinella sp. , Phakellia carteri and Lissondendryx sp. The complete synthesis of Halichondrin B was made public in 1992 (Non-Patent Document 1 and Patent Document 1). Halichondrin B shows tubulin polymerization, microtubule aggregation, beta-tubulin crosslinking, binding of GTP and Vinblastine to tubulin, and tubulin-dependent GTP hydrolysis in vitro, and also shows anti-tumor activity both in vitro and in vivo. [0003]
- Patent Document 1 Specification of U.S. Patent No. 5,338,865
- Patent Document 2 Specification of U.S. Patent No. 5,338,865
- Non-Patent Document 3
- One of key steps in the synthesis path of B- 1939 described in Patent Document 2 is the step of cyclizing an intermediate ER-118049 by intramolecular coupling to obtain ER- 118047/048 (paragraph [00206] of Patent Document 2).
- This ER- 118049 is obtained by desulfonylation of ER-804030 (paragraph [00205] of Patent Document 2).
- SmI 2 is used as a reducing agent.
- SmI 2 is expensive and is not a compound which is easily available in large quantities, and also SmI 2 is not easy to handle since it is very unstable when exposed to oxygen in the air.
- Cr(III)X 3 is preferably used as the trivalent chromium compound, hi the formula, X represents a halogen atom and X is preferably a chlorine (Cl) or bromine
- R and R 1 as ligands of formula (II) shown below used in the present invention represent t-butyl, phenyl, or nonyl, and R 2 and R 2 represent a hydrogen atom, or R and R are preferably combined to form a fused ring together with a pyridine ring to which they are attached.
- a metallocene compound selected from the group consisting of Ti, Zr and Hf compounds, containing a cyclopentadienyl ring for the desulfonylation reaction of the present invention.
- the amount of a trivalent chromium compound to be used can be decreased by using the metallocene compound.
- the desulfonylation reaction of the present invention proceeds under mild conditions.
- the desulfonylation reaction is preferably carried out at a temperature of 20 to 30°C.
- the solvent used for the desulfonylation reaction of the present invention is particularly preferably a mixture of one or more kinds selected from the group consisting of tetrahydrofuran, dimethoxyethane, methyl t-butylether, dimethylformamide, methanol, and acetonitrile.
- a compound (I) is obtained by intramolecular coupling of a compound (IV) and a compound (III) is obtained by desulfonylation of the compound (I).
- the compound (FV) includes ER-804030 disclosed in paragraph [00203] of the pamphlet of International Publication No. WO 2005/118565.
- the compound (III) obtained by the reaction path of the aforementioned Scheme 1 is ER- 118047/048 described in paragraph [00205] of the pamphlet of International Publication No. WO 2005/118565.
- R 3 represents R or OR
- R represents a hydrogen atom, a halogen atom, a C 1-4 halogenated aliphatic group, benzyl, or a C 1-4 aliphatic group.
- the halogen atom include fluorine, chlorine, bromine and iodine atoms and, among these atoms, fluorine and chlorine atoms are preferred.
- the C 1-4 halogenated aliphatic group include, but are not limited to, fluoromethyl, trifluoromethyl, and chloromethyl.
- C 1-4 alkyl group examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and t-butyl.
- a methoxy (OMe) group is particularly preferred as R 3 .
- Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.
- the aryl group represented by Ar is preferably an aromatic hydrocarbon group having 6 to 10 carbon atoms, and examples thereof include a phenyl group and a naphthyl group.
- the aryl group may or may not further have one or more substituent groups, and examples of the substituent groups include, but are not limited to, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a halogen atom such as a fluorine or chlorine atom, and C 1-6 alkoxy.
- Specific examples of Ar include a phenyl group, a 2-methylphenyl group, a 4-methylphenyl group, and a naphthyl group.
- Ar is particularly preferably a phenyl group.
- Ar may be a substituted or unsubstituted heteroaryl group.
- the substituent group includes the same substituent groups as those of the aryl group.
- Examples of the heteroaryl group include a quinolinyl group.
- PG 1 , PG 2 and PG 4 in formula (I) each independently represents a protective group of a hydroxyl group.
- a suitable protective group of the hydroxyl group is known in this field and includes protective groups described in "Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999".
- PG 1 , PG 2 and PG 4 are independently selected, as a group containing the oxygen atom to which they are attached, from esters, ethers, silylethers, alkylethers, aralkylethers, and alkoxyalkylethers.
- esters examples include formates, acetates, carbonates, and sulfonates. Specific examples thereof include formate, benzoylformate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4- oxopentanoate, 4,4-(ethylenedithio)pentanoate, (trimethylacetyl)pivaloate, crotonate, 4- methoxy-crotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate, or carbonates (for example, methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2- (trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl carbonates).
- formate benzo
- silylethers examples include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t- butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers.
- alkylethers examples include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t- butyl, allyl, and allyloxycarbonyl ethers or a derivative group thereof.
- alkoxyalkylethers examples include ethers such as methoxymethyl, methylthiomethyl, (2- methoxyethoxy)methyl, benzyloxymethyl, ⁇ -(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers.
- arylalkylethers include benzyl, p- methoxybenzyl (MPM), 3,4-dimethoxybenzyl, 0-nitrobenzyl, p-nitrobenzyl, p- halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.
- one or more of PG , PG and PG 4 are silylethers or aryl alkyl ethers, hi another aspect, at least one of PG 1 , PG 2 and PG 4 is t-butyldimethylsilyl or benzoyl. In a particularly preferred aspect, PG 1 , PG 2 and PG 4 represent t-butyldimethylsilyl. [0022]
- PG 1 and PG 2 , and two PG 4 may form a diol protective group such as acetal or ketal together with the oxygen atom to which they are attached.
- the diol protective group include methylene, ethylidene, benzylindene, isopropylidene, cyclohexylidene, cyclopentylindene, a silylene derivative group such as di-t-butylsilylene or 1,1,3,3-tetraisopropylsiloxanylidene, cyclic carbonate, and cyclic boronate.
- a compound of formula (I) (hereinafter referred to as “compound I”) can be synthesized by intramolecular coupling of a compound of formula (IV) (hereinafter referred to as “compound IV”).
- the compound IV is available based on the synthesis method described in detail in WO2005/118565.
- a compound IV having various protective groups of a hydroxyl group can be synthesized by substituting the protective group of the hydroxyl group with a desired protective group in the synthesis method.
- a compound I is obtained by intramolecular coupling of an aldehyde group and a vinyl iodide group in the compound IV.
- This coupling reaction can be carried out using Ni(II)-Cr(II) as described in the aforementioned Patent Document 1 and paragraph [00206] of WO2005/118565. [0025]
- a compound of formula (III) (hereinafter referred to as "compound III”) can be synthesized by desulfonylation of a compound I. .
- the present inventors have found that desulfonylation proceeds under mild conditions to obtain a compound III in a high yield by treating a compound I with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in the presence of a specific ligand.
- desulfonylation of a compound I can be carried out by treating the compound I with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in a solvent in the presence of a ligand represented by formula (II) shown below: [Chemical 6]
- this treatment can be carried out by mixing an organosulfone compound, a trivalent chromium compound, manganese metal and/or zinc metal as raw materials in a solvent in the presence of a ligand of formula (II).
- R 1 and R 1 each independently represents a C 3-12 alkyl group, or an unsubstituted or substituted phenyl group.
- the C 3-12 alkyl group includes a straight-chain, branched or cyclic alkyl group and examples thereof include propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl groups, and isomers thereof.
- t-butyl and nonyl groups are particularly preferred.
- substituent group in a phenyl group examples include, but are not limited to, halogen atoms (for example, fluorine and chlorine atoms), C 1-12 alkyl groups (for example, straight-chain, branched and cyclic alkyl groups), and C 1-6 alkoxy groups (for example, methoxy, ethoxy, propoxy and butoxy groups).
- halogen atoms for example, fluorine and chlorine atoms
- C 1-12 alkyl groups for example, straight-chain, branched and cyclic alkyl groups
- C 1-6 alkoxy groups for example, methoxy, ethoxy, propoxy and butoxy groups.
- a particularly preferred unsubstituted or substituted phenyl group is an unsubstituted phenyl group.
- R and R each independently represents a hydrogen atom or a C 1-6 alkyl group.
- the C 1-6 alkyl group includes a straight-chain, branched or cyclic alkyl group, and examples thereof include methyl, ethyl, propyl, butyl, pentyl and hexyl groups, and isomers thereof.
- R 2 and R 2 may be combined to form a fused ring together with two pyridine rings to which they are attached.
- the fused ring include 1,10- phenanthroline, 5,6-dimethyl- 1 , 10-phenanthroline, 5 ,6-dihydro- 1 , 10-phenanthroline, and 4,7-diphenyl- 1,10-phenanthroline.
- the solvent used for the desulfonylation reaction may be any solvent as long as it does not inhibit the desulfonylation reaction. These solvents can be used alone, or two or more kinds of them can be used in combination. Examples of preferred solvents include tetrahydrofuran (THF), dimethoxyethane (DME), methyl t-butylether (MTBE), dimethylformamide (DMF), methanol, and acetonitrile, and it is preferred to use one kind of solvent selected from these solvents, or a mixture of two or more kinds selected from them. [0029]
- a known trivalent chromium compound can be used for the desulfonylation reaction of the present invention.
- the trivalent chromium compound a known organic chromium compound and a known inorganic chromium compound can be used, and an inorganic chromium compound is preferred.
- a particularly preferred trivalent chromium compound is a chromium(III) halide represented by Cr(III)X 3 (wherein X represents a halogen atom). X is preferably Cl (chlorine) or Br (bromine).
- Particularly preferred trivalent chromium compounds are CrCl 3 anhydride and CrCl 3 •
- one or more kinds of metals selected from manganese and zinc are used together with the trivalent chromium compound. Since the reaction rate can be enhanced, powdered manganese and powdered zinc are preferably used.
- the trivalent chromium compound may be used in the amount of 1 molar equivalent or more, particularly 1 to 10 molar equivalents, and preferably 2 to 5 molar equivalents, based on the organosulfone compound as a starting material.
- the amount of the trivalent chromium compound is not limited to the above range.
- the amount of the trivalent chromium compound can be remarkably decreased by adding a small amount of a metallocene compound selected from zirconocene dichloride.
- the manganese metal and/or zinc metal to be used together with the trivalent chromium compound may be used in the amount of 1 molar equivalent or more, particularly 1 to 100 molar equivalents, preferably from 3 to 30 molar equivalents, and more preferably 5 to 20 molar equivalents, based on the organosulfone compound as a starting material. Usually, it is preferred to use manganese metal and/or zinc metal which have larger molar equivalents than those of the trivalent chromium compound to be used.
- the desulfonylation reaction of the present invention can be carried out at a temperature of 5 to 50°C, and particularly preferably 20 to 30 0 C, but the reaction temperature is not specifically limited.
- a significant feature of the desulfonylation reaction of the present invention is that it can be carried out at room temperature. However, the desulfonylation reaction can also be carried out at a temperature which is higher or lower than room temperature (20 to 30 0 C).
- the objective desulfonylated product is obtained by mixing a reaction mixture with stirring at a desired reaction temperature.
- the desulfonylation reaction is preferably carried out under the atmosphere of an inert gas, for example, nitrogen or argon.
- the present inventors have found that, by using a metallocene compound together with a trivalent chromium compound in the desulfonylation reaction of the present invention, a desulfonylation reaction product is obtained in a high yield even when the amount of the trivalent chromium compound to be used is less than 1 molar equivalent based on the organosulfone compound.
- a desulfonylated product is obtained in a high yield even when the trivalent chromium compound is used in the amount of less than 1 molar equivalent, for example, 0.2 molar equivalents, based on the organosulfone compound. Therefore, the amount of the trivalent chromium compound can be remarkably decreased by adding the metallocene compound.
- Each amount of the metallocene compound and the trivalent chromium compound to be used for the desulfonylation reaction can be adjusted to a suitable amount so as to obtain a desired desulfonylated product in a desired yield.
- metallocene compound examples include compounds having a cyclopentadienyl ring of a transition metal selected from the group consisting of Group 4 transition metals (Ti, Zr, and Hf) of the Periodic Table. These compounds are known and include, for example, various metallocene compounds described in Japanese Unexamined Patent Application, First Publication No. 2006-63158 (paragraphs [0024] to [0031]).
- the metallocene compound examples include bis(cyclopentadienyl)zirconium dichloride; a bis(mono- or polyalkyl substituted cyclopentadienyl)zirconium dichloride such as bis(methylcyclopentadienyl)zirconium chloride or bisf ⁇ entamethylcyclopentadienytyzirconium chloride; bis(indenyl)zirconium dichloride; a zirconium compound such as a bis(mono- or polyalkyl substituted indenyl)zirconium dichloride; and titanium and hafnium compounds, each having a chemical structure in which a zirconium atom of these compounds is replaced by a titanium or hafnium atom.
- a Zr compound is preferred and bis(cyclopentadienyl)zirconium dichloride is particularly preferred.
- the desulfonylation reaction of the present invention since a desulfonylated product can be obtained in a high yield under conditions at room temperature, desirable results can be obtained even when an unstable compound is used as a starting material. Since this reaction can be carried out only by stirring all raw materials in a solvent at room temperature, it is easy to control the reaction conditions.
- ER-804030 used in the following Examples was synthesized in accordance with the method described in the Examples of the pamphlet of International Publication No. WO 2005/118565.
- Commercially available products were used as a ligand II, a trivalent chromium compound, manganese metal, zirconocene dichloride and a solvent in the reaction.
- THF denotes tetrahydrofuran
- DME denotes dimethoxyethane
- ACN denotes acetonitrile
- HPLC denotes high-performance liquid chromatography
- TLC denotes thin-layer chromatography
- TBS denotes t- butyldimethylsilyl
- Cp denotes a cyclopentadienyl group, respectively.
- a CrCl 3 /4,4'-di-t-butyl-bipyridyl catalyst and aNiCl 2 /2,9-dimethyl-l,10- phenanthroline catalyst used in the following Examples were prepared in accordance with the method described in Namba, K.; Kishi, Y. J. Am. Chem. Soc. 2005, 127, 15382. [0039]
- NiCl 2 /2,9-dimethyl-l,10-phenanthroline catalyst was prepared in the following manner.
- a NiCl 2 -DME complex (660 mg, 3.0 mmol, 1.0 molar equivalent), 2,9-dimethyl-l,10-phenanthroline (Neocuproine; 659 mg, 3.0 mmol, 1.0 molar equivalent) were charged after weighing and, after the reaction vessel was depressurized, the atmosphere in the reaction vessel was replaced by nitrogen. Then, anhydrous acetonitrile (40 ml) was added and the contents were well mixed. Ultrasonic waves were applied to the resultant reaction solution for one minute, followed by standing for 20 minutes. The supernatant was removed and a yellow precipitate was dried under reduced pressure to obtain 668 mg of a yellow powder
- Example 1 Production Example 1 of ER-413207
- the organic layer was washed with an aqueous 10% citric acid solution (6.0ml) to isolate the organic layer.
- the aqueous layer was reextracted with hexane (3.0 ml) and the hexane layer was mixed with the organic layer.
- Hexane (2.0 ml) was added to the organic layer and, after washing with
- Example 2 Production Example 2 of ER-413207
- anhydrous THF solution (4.0 ml) of ER- 804030 (200 mg, 0.126 mmol) was added and the resultant mixture was stirred under a nitrogen atmosphere at room temperature (25 0 C) for 6 hours.
- the reaction solution was diluted with ethyl acetate (100 ml) under air.
- the resultant solution was filtered through silica gel (16 g) and the silica gel was rinsed in turn with ethyl acetate (40 ml) and heptane (40 ml). The filtrate and the wash were combined and concentrated to obtain an ER-413207 crude product in a yield of 91.2% (HPLC quantitative value).
- ER-807063 (1.9 g, 6.40 mmol) was weighed and placed in a reaction vessel, acetonitrile (27 ml) was added and dissolved.
- CrCl 2 800 mg, 6.51 mmol
- triethylamine 0.8 ml, 6.00 mmol
- the reaction mixture was stirred at a temperature within a range from 15 to 21 °C for 3 hours while gradually heating and heptane (25 ml) was introduced into the reaction mixture.
- the reaction mixture was filtered on a celite pad and then the celite pad was rinsed with heptane (10 ml) and acetonitrile (10 ml).
- the upper layer (heptane layer) of the resultant solution was isolated and the lower layer (acetonitrile layer) was extracted with heptane (30 ml).
- the combined heptane layer was washed twice with acetonitrile (10 ml) and then concentrated to obtain 766 mg of an ER-413207 crude product.
- This crude product was purified by silica gel column chromatography (eluate:heptane/ethyl acetate) to obtain 673.3 mg (76.7%, 0.460 mmol) of ER-413207 as a colorless solid.
- Example 4 Production Example 4 of ER-413207
- Example 5 Production Example 1 of ER- 118047/048
- the reaction mixture was concentrated and methanol was added again, followed by stirring and further concentration to obtain the objective compound ER- 118047/048 as a diastereomer mixture.
- the resultant crude product was quantitatively determined by a HPLC external standard method to determine the yield. As a result, the yield was 93.6%.
- the crude product was purified by silica gel column chromatography (eluate: heptane/ethyl acetate) to obtain a purified product as a colorless solid.
- Example 7 Production Example 3 of ER- 118047/048
- the reaction mixture After terminating the reaction by adding heptane (about 0.5 ml) to the reaction mixture, the reaction mixture was analyzed by a HPLC external standard method and the objective product was quantitatively determined thereby determining the yield of the objective product. As a result, the yield was more than 99% (diastereomer mixture).
- Example 8 Production Example 4 of ER- 118047/048
- NiCl 2 /2,9- dimethyl-l,10-phenanthroline complex (12.8 mg, 0.0378 mmol, 0.10 molar equivalents) was added to this reaction solution, followed by stirring at room temperature for 30 minutes.
- a THF solution (15 ml) of ER-804030 (600 mg) was added through 15 minutes, followed by stirring at room temperature for 2 hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0820519A BRPI0820519A2 (en) | 2007-11-16 | 2008-11-14 | intermediate for the synthesis of the halicondrin b analogue and desulfonylation reaction used for the intermediate |
CN2008801240310A CN101910180A (en) | 2007-11-16 | 2008-11-14 | Novel intermediate for halichondrin B analog synthesis and novel desulfonylation reaction used for the intermediate |
JP2010519043A JP5134686B2 (en) | 2007-11-16 | 2008-11-14 | Novel intermediates for the synthesis of halichondrin B analogues and novel desulfonylation reactions for use in said intermediates |
CA2705383A CA2705383A1 (en) | 2007-11-16 | 2008-11-14 | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
MX2010005340A MX2010005340A (en) | 2007-11-16 | 2008-11-14 | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate. |
EP08850157A EP2220094A1 (en) | 2007-11-16 | 2008-11-14 | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
IL205761A IL205761A0 (en) | 2007-11-16 | 2010-05-13 | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98849607P | 2007-11-16 | 2007-11-16 | |
JP2007298074 | 2007-11-16 | ||
JP2007-298074 | 2007-11-16 | ||
US60/988,496 | 2007-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009064029A1 true WO2009064029A1 (en) | 2009-05-22 |
Family
ID=40344710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/071167 WO2009064029A1 (en) | 2007-11-16 | 2008-11-14 | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090203771A1 (en) |
EP (1) | EP2220094A1 (en) |
JP (1) | JP5134686B2 (en) |
CN (1) | CN101910180A (en) |
BR (1) | BRPI0820519A2 (en) |
CA (1) | CA2705383A1 (en) |
IL (1) | IL205761A0 (en) |
MX (1) | MX2010005340A (en) |
RU (1) | RU2010118063A (en) |
WO (1) | WO2009064029A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7982060B2 (en) | 2004-06-03 | 2011-07-19 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
US8093410B2 (en) * | 2007-10-03 | 2012-01-10 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US8148554B2 (en) | 1998-06-17 | 2012-04-03 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
US8598373B2 (en) | 2008-04-04 | 2013-12-03 | Eisai R&D Management Co., Ltd. | Halichondrin B analogs |
WO2015066729A1 (en) | 2013-11-04 | 2015-05-07 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b |
US9303039B2 (en) | 2013-12-06 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
WO2016179607A1 (en) | 2015-05-07 | 2016-11-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
WO2018187331A1 (en) | 2017-04-05 | 2018-10-11 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
WO2019099646A1 (en) | 2017-11-15 | 2019-05-23 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
WO2019136145A1 (en) | 2018-01-03 | 2019-07-11 | Eisai R&D Management Co., Ltd. | Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof |
US10392400B2 (en) | 2016-11-11 | 2019-08-27 | President And Fellows Of Harvard College | Palladium-mediated ketolization |
US10556910B2 (en) | 2014-06-30 | 2020-02-11 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
US10676481B2 (en) | 2016-02-12 | 2020-06-09 | Eisai R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
WO2020255164A1 (en) | 2019-06-21 | 2020-12-24 | Council Of Scientific And Industrial Research | A chemo-enzymatic process for the preparation of homopropargylic alcohol |
US11136335B2 (en) | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
US11548898B2 (en) | 2017-07-06 | 2023-01-10 | President And Fellows Of Harvard College | Synthesis of halichondrins |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017206439A (en) * | 2014-08-27 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Method for producing antitumor agent using homogenizer |
CN106946906A (en) * | 2017-05-05 | 2017-07-14 | 重庆泰濠制药有限公司 | A kind of compound and its preparation method and application |
WO2018217894A1 (en) * | 2017-05-24 | 2018-11-29 | Eisai R&D Management Co., Ltd. | Fluorine-labelled halichondrin derivatives and related methods of synthesis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118565A1 (en) * | 2004-06-03 | 2005-12-15 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
-
2008
- 2008-11-14 BR BRPI0820519A patent/BRPI0820519A2/en not_active IP Right Cessation
- 2008-11-14 JP JP2010519043A patent/JP5134686B2/en not_active Expired - Fee Related
- 2008-11-14 WO PCT/JP2008/071167 patent/WO2009064029A1/en active Application Filing
- 2008-11-14 CN CN2008801240310A patent/CN101910180A/en active Pending
- 2008-11-14 MX MX2010005340A patent/MX2010005340A/en not_active Application Discontinuation
- 2008-11-14 CA CA2705383A patent/CA2705383A1/en not_active Abandoned
- 2008-11-14 EP EP08850157A patent/EP2220094A1/en not_active Withdrawn
- 2008-11-14 RU RU2010118063/04A patent/RU2010118063A/en unknown
- 2008-11-14 US US12/271,731 patent/US20090203771A1/en not_active Abandoned
-
2010
- 2010-05-13 IL IL205761A patent/IL205761A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118565A1 (en) * | 2004-06-03 | 2005-12-15 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
Non-Patent Citations (1)
Title |
---|
ZHENG WANJUN ET AL: "Macrocyclic ketone analogues of halichondrin B", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 22, 15 November 2004 (2004-11-15), pages 5551 - 5554, XP004598592, ISSN: 0960-894X * |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8148554B2 (en) | 1998-06-17 | 2012-04-03 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
US8975422B2 (en) | 2004-06-03 | 2015-03-10 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
USRE45324E1 (en) | 2004-06-03 | 2015-01-06 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
US9303050B2 (en) | 2004-06-03 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
USRE47797E1 (en) | 2004-06-03 | 2020-01-07 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
US8618313B2 (en) | 2004-06-03 | 2013-12-31 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
US8445701B2 (en) | 2004-06-03 | 2013-05-21 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
US7982060B2 (en) | 2004-06-03 | 2011-07-19 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
USRE46965E1 (en) | 2004-06-03 | 2018-07-24 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
US8884031B2 (en) | 2004-06-03 | 2014-11-11 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
US10214539B2 (en) | 2007-10-03 | 2019-02-26 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US8093410B2 (en) * | 2007-10-03 | 2012-01-10 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US10717743B2 (en) | 2007-10-03 | 2020-07-21 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9802953B2 (en) | 2007-10-03 | 2017-10-31 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US8987479B2 (en) | 2007-10-03 | 2015-03-24 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9604993B2 (en) | 2007-10-03 | 2017-03-28 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9469651B2 (en) | 2008-04-04 | 2016-10-18 | Eisai R&D Management Co., Ltd. | Halichondrin B analogs |
US9206194B2 (en) | 2008-04-04 | 2015-12-08 | Eisai R&D Management Co., Ltd. | Halichondrin B analogs |
US8598373B2 (en) | 2008-04-04 | 2013-12-03 | Eisai R&D Management Co., Ltd. | Halichondrin B analogs |
US8350067B2 (en) | 2010-01-26 | 2013-01-08 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US10494388B2 (en) | 2010-01-26 | 2019-12-03 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US9382262B2 (en) | 2010-01-26 | 2016-07-05 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US8927597B2 (en) | 2010-01-26 | 2015-01-06 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US9856276B2 (en) | 2010-01-26 | 2018-01-02 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
US10221189B2 (en) | 2013-11-04 | 2019-03-05 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B |
US11643418B2 (en) | 2013-11-04 | 2023-05-09 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B |
US10934307B2 (en) | 2013-11-04 | 2021-03-02 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B |
US9783549B2 (en) | 2013-11-04 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B |
EP3689881A1 (en) | 2013-11-04 | 2020-08-05 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b |
WO2015066729A1 (en) | 2013-11-04 | 2015-05-07 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b |
US10611773B2 (en) | 2013-11-04 | 2020-04-07 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B |
US10450324B2 (en) | 2013-12-06 | 2019-10-22 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US9695188B2 (en) | 2013-12-06 | 2017-07-04 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US9303039B2 (en) | 2013-12-06 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US10030032B2 (en) | 2013-12-06 | 2018-07-24 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US11155562B2 (en) | 2014-06-30 | 2021-10-26 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
US10556910B2 (en) | 2014-06-30 | 2020-02-11 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
US10633392B2 (en) | 2015-04-30 | 2020-04-28 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
US11220513B2 (en) | 2015-04-30 | 2022-01-11 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
WO2016179607A1 (en) | 2015-05-07 | 2016-11-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US10308661B2 (en) | 2015-05-07 | 2019-06-04 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US10913749B2 (en) | 2015-05-07 | 2021-02-09 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US10676481B2 (en) | 2016-02-12 | 2020-06-09 | Eisai R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
US11136335B2 (en) | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
US10392400B2 (en) | 2016-11-11 | 2019-08-27 | President And Fellows Of Harvard College | Palladium-mediated ketolization |
US10844073B2 (en) | 2016-11-11 | 2020-11-24 | President And Fellows Of Harvard College | Palladium-mediated ketolization |
EP4119563A2 (en) | 2017-04-05 | 2023-01-18 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US10954249B2 (en) | 2017-04-05 | 2021-03-23 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
WO2018187331A1 (en) | 2017-04-05 | 2018-10-11 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US11725015B2 (en) | 2017-04-05 | 2023-08-15 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
US11548898B2 (en) | 2017-07-06 | 2023-01-10 | President And Fellows Of Harvard College | Synthesis of halichondrins |
US11814398B2 (en) | 2017-11-15 | 2023-11-14 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
WO2019099646A1 (en) | 2017-11-15 | 2019-05-23 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
US11407762B2 (en) | 2017-11-15 | 2022-08-09 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
WO2019136145A1 (en) | 2018-01-03 | 2019-07-11 | Eisai R&D Management Co., Ltd. | Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof |
US11542269B2 (en) | 2018-01-03 | 2023-01-03 | Eisai R&D Management Co., Ltd. | Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof |
US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
WO2020255164A1 (en) | 2019-06-21 | 2020-12-24 | Council Of Scientific And Industrial Research | A chemo-enzymatic process for the preparation of homopropargylic alcohol |
Also Published As
Publication number | Publication date |
---|---|
CA2705383A1 (en) | 2009-05-22 |
JP2011504166A (en) | 2011-02-03 |
IL205761A0 (en) | 2010-11-30 |
JP5134686B2 (en) | 2013-01-30 |
BRPI0820519A2 (en) | 2017-05-23 |
US20090203771A1 (en) | 2009-08-13 |
MX2010005340A (en) | 2010-12-21 |
RU2010118063A (en) | 2011-12-27 |
CN101910180A (en) | 2010-12-08 |
EP2220094A1 (en) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090203771A1 (en) | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate | |
EP2522663B1 (en) | Intermediates for the preparation of halichondrin B | |
KR100516593B1 (en) | Highly lipophilic camptothecin derivatives | |
JPH07504664A (en) | Halichondrins and related compounds | |
EP3187500B1 (en) | Method for producing antitumor agent using a homogenizer | |
TWI675842B (en) | Intermediates of eribulin and their preparation methods | |
WO2006070671A1 (en) | 12-position substituted mutilin derivative | |
FR2800374A1 (en) | NEW DERIVATIVES OF 9- (3,5-DIMETHOXYPHENYL) -5,8,8A, 9- TETRAHYDROFURO [3 ', 4': 6.7] NAPHTO [2,3-D] [1,3] DIOXOL-6 ( 5AH) - ONE, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
CZ294311B6 (en) | Reduction process of prochiral ketone | |
JP5960130B2 (en) | Preparation of tesetaxel and related compounds and corresponding synthetic intermediates | |
CN111793047B (en) | Preparation method of eribulin intermediate | |
CN110804012B (en) | Method for reducing mercaptal or thioketone for desulfurization | |
EP0346356A1 (en) | Synthesis process and oxygen-containing heterocyclic products thereof | |
CN111499600A (en) | Synthesis method of polysubstituted 2, 3-dihydrofuran compound | |
Kudo et al. | Synthesis of 1-acetyl-2-silyoxycycloheptane derivatives via highly stereoselective formal [5+ 2] cycloaddition reaction | |
US5019590A (en) | Antimalarial analogs of artemisinin | |
US6723849B1 (en) | Process for making camptothecin derivatives | |
KR20130115395A (en) | Process for producing tricyclic ketone | |
US20030187282A1 (en) | Process for preparation of 7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid derivatives | |
CN113710674B (en) | Diastereoselective process for preparing maytansinoids containing thiols or disulfides and intermediates thereof | |
US5180840A (en) | Process for preparing analogs of artemisinin | |
JP3565587B2 (en) | Novel synthesis of 15-hydroxymilbemycin derivatives | |
CN116655718A (en) | Togliflozin five-membered ring impurity and preparation method thereof | |
US9284327B2 (en) | Taxane compounds, compositions and methods | |
CA2787722C (en) | A series of artemisinin derivatives and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880124031.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08850157 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2712/CHENP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2705383 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 205761 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010519043 Country of ref document: JP Ref document number: MX/A/2010/005340 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008850157 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010118063 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0820519 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100513 |